Table 1 Demographic and clinical characteristics in patients

Gender, male, n (%)

49(60.49)

624(60.82)

0.954

Age, mean ± SD (years)

64.47 ± 9.34

63.34 ± 11.48

0.636

Hypertension, n (%)

54(66.67)

598(58.34)

0.143

Diabetes mellitus, n (%)

17(20.99)

174(16.96)

0.356

Atrial fibrillation, n (%)

15(18.52)

182(17.74)

0.860

Hyperlipidemia, n (%)

3(3.70)

69(6.73)

0.288

prior stroke/TIA, n (%)

2(2.47)

100(9.75)

0.029

Current smoking, n (%)

20(24.69)

361(35.19)

0.056

Glucose, mean (SD), mmol/L

9.00 ± 4.35

7.58 ± 2.87

0.001

WBC, mean (SD), × 10⁹/L

8.32 ± 2.85

7.87 ± 2.70

0.216

FBG, mean (SD), g/L

3.47 ± 1.24

3.23 ± 1.23

0.040

LDL, mean (SD), mmol/L

3.20 ± 0.90

2.92 ± 0.96

0.003

TC, mean (SD), mmol/L

5.08 ± 1.16

4.85 ± 1.20

0.021

SBP on admission, mean (SD), mmHg

152.30 ± 18.56

147.57 ± 21.09

0.039

DBP on admission, mean (SD), mmHg

88.35 ± 11.86

85.70 ± 12.68

0.038

SBP at 2 hours after thrombolysis, mean (SD), mmHg

150.05 ± 22.31

143.03 ± 19.80

0.002

DBP at 2 hours after thrombolysis, mean (SD), mmHg

87.19 ± 14.28

83.42 ± 12.38

0.015

NIHSS on admission, IQR

12(3–28)

11(0–40)

0.559

Pre-admission mRS 0–2, n (%)

80(100)

1002(92.75)

0.398

 Taking aspirin, n (%)

31(38.27)

669(65.20)

< 0.0001

 Taking clopidogrel, n (%)

11(13.58)

242(23.59)

0.039

 Taking other antiplatelets, n (%)

11(13.58)

156(15.20)

0.694

 Taking hypoglycemic drugs, n (%)

0(0.00)

9(0.88)

1.000

Median door-to-needle time, IQR, h

1.82 ± 0.95

2.60 ± 9.90

0.971

TOAST subtypes

0.080

 LAA, n (%)

43(55.13)

553(54.11)

 SAO, n (%)

4(5.13)

113(11.06)

 CE, n (%)

22(28.21)

191(18.69)

 Other, n (%)

9(11.54)

165(16.14)